Celltrion announced on the 12th that it has decided to carry out an additional share buyback worth approximately 100 billion won through a board meeting. The shares being repurchased this time amount to about 589,276 shares, and the buyback is set to take place on the 21st.
Including today's decision, the total amount of share buybacks completed or decided by Celltrion since January has reached approximately 900 billion won. This year's share buyback amount is about 450 billion won, surpassing last year's total of approximately 436 billion won. Notably, last month, Chairman Seo Jeong-jin of Celltrion Group took responsibility for management by deciding to purchase 50 billion won worth of shares in the market. The holding company Celltrion Holdings decided on a share buyback worth 100 billion won, while group affiliate Celltrion Skin Cure opted for a purchase of 50 billion won.
Recently, a plan for employee stock ownership was conducted, closing subscriptions at approximately 40 billion won. The number of applicants reached around 850. Despite uncertainties such as the U.S. government's tariff policy and short-selling policy, Celltrion continues to enhance its product and market competitiveness in the global market. The company achieved its goal of establishing an 11-product biopharmaceutical (biosimilar) product line by the end of last year ahead of schedule. Currently, the company is speeding up the approval process for 22 types of biosimilars by 2030, and it plans to enter overseas clinical trials for its next-generation antibody-drug conjugate (ADC) new drugs this year, in addition to developing 13 new drug candidates by 2028.
In particular, it is implementing a value-up program targeting an average shareholder return rate of 40% over the next three years, with plans to continue shareholder-friendly policies to prioritize the protection of shareholder interests.
A Celltrion official noted, "Despite the ongoing expansion of uncertainty and the undervaluation of corporate value, Celltrion is strengthening its competitiveness and gradually advancing as a global large pharmaceutical company," and added, "We will prioritize enhancing shareholder value and do our best to ensure that the company and investors can grow together."